Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea ...

Hims & Hers Health stock has seen its fair value estimate trimmed from about $46.00 to roughly $44.36 per share, even as analysts grow more optimistic about its long term revenue trajectory. Stronger ...

Delving into the details, we found 53% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $373,316, and 7 were calls, valued ...

The financial market is a machine powered by shifting opinions, and when the Federal Reserve announced its latest interest rate cut, those opinions pushed capital into healthcare and financial stocks.

Hims & Hers Health ($HIMS) is strengthening its position in the UK with the launch of weight-loss programs. This launch will ...

Virtual healthcare platforms are redefining patient access to care, with Hims & Hers Health, Inc. HIMS and GoodRx Holdings, Inc. GDRX among the leaders in this digital shift. HIMS is a ...

Hims & Hers Health Inc. (NYSE: HIMS) stock is holding onto a slight gain the day after the company delivered a mixed third-quarter earnings report. The caution centers around the company’s valuation, ...

Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc.

Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...

Hims & Hers shows platform expansion, verticalization, new Labs offerings, slower FCF growth and strong long-term revenue targets. Learn why HIMS stock is a buy.

The next-generation healthcare services specialist has launched offerings in a new segment. This is laser-focused on female health. Investors liked what they heard about the company's latest expansion ...